AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research.
By Scott Kanowsky
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with